CV SCIENCES LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in CV Sciences, Inc. to Contact the Firm

NEW YORK–(BUSINESS WIRE)–Faruqi & Faruqi, LLP, a leading national securities law firm, reminds
investors in CV Sciences, Inc. (“CV Sciences” or the “Company”) (Other
OTC:CVSI) of the October 23, 2018 deadline to seek the role of lead
plaintiff in a federal securities class action that has been filed
against the Company.

If you invested in CV Sciences stock or options between June 19, 2017
and August 20, 2018
and would like to discuss your legal rights, click
here
: www.faruqilaw.com/CVSI.
There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at
877-247-4292
or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

The lawsuit has been filed in the U.S. District Court for the District
of Nevada on behalf of all those who purchased CV Sciences common stock
between June 19, 2017 and August 20, 2018 (the “Class Period”). The
case, Smith v. CV Sciences, Inc. et al, No. 18-cv-01602 was filed
on August 24, 2018, and has been assigned to Judge Jennifer A. Dorsey.

The lawsuit focuses on whether the Company and its executives violated
federal securities laws by failing to disclose that the U.S. Patent and
Trademark Office (the “USPTO”) rejected the patent for CVSI-007, the
Company’s lead drug candidate for the treatment of smokeless tobacco
addiction.

Specifically, on August 20, 2018, Citron Research reported on Twitter
that the Company had failed to disclose that the USPTO rejected its
patent for CVSI-007 on December 14, 2017.

Following the report, CV Science’s share price fell from $6.61 per share
on August 17, 2018 to a closing price of $4.21 on August 20, 2018—a
$2.40 or a 36.31% drop.

The court-appointed lead plaintiff is the investor with the largest
financial interest in the relief sought by the class who is adequate and
typical of class members who directs and oversees the litigation on
behalf of the putative class. Any member of the putative class may move
the Court to serve as lead plaintiff through counsel of their choice, or
may choose to do nothing and remain an absent class member. Your ability
to share in any recovery is not affected by the decision to serve as a
lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding
CV Sciences’ conduct to contact the firm, including whistleblowers,
former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is
Faruqi & Faruqi, LLP (www.faruqilaw.com).
Prior results do not guarantee or predict a similar outcome with respect
to any future matter. We welcome the opportunity to discuss your
particular case. All communications will be treated in a confidential
manner.

Contacts

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New
York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone:
(877) 247-4292 or (212) 983-9330

leverton

I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.coom for scheduling information.